PriceTargets.com logo

Genus - GNS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 4,500
  • Forecasted Upside: 56.58%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 2,874 As of 03/31/2023 01:00 AM ET
▲ +36 (1.27%)

This chart shows the closing price for GNS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Genus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNS

Analyst Price Target is GBX 4,500
▲ +56.58% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Genus in the last 3 months. The average price target is GBX 4,500, with a high forecast of GBX 4,500 and a low forecast of GBX 4,500. The average price target represents a 56.58% upside from the last price of GBX 2,874.

This chart shows the closing price for GNS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Genus. This rating has held steady since December 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/12/2022Peel HuntReiterated RatingHoldGBX 4,500
12/7/2021Liberum CapitalReiterated RatingBuyGBX 5,740
11/24/2021Liberum CapitalLower TargetBuyGBX 6,000 ➝ GBX 5,740
11/3/2021Liberum CapitalReiterated RatingBuyGBX 6,000
9/9/2021Liberum CapitalReiterated RatingBuyGBX 5,630
6/29/2021CitigroupReiterated RatingHoldGBX 5,500
6/29/2021Numis SecuritiesReiterated RatingAddGBX 5,500
6/23/2021Liberum CapitalReiterated RatingBuyGBX 5,630
6/22/2021Peel HuntReiterated RatingBuyGBX 5,500
6/22/2021Peel HuntReiterated RatingBuyGBX 5,500
1/18/2021Liberum CapitalBoost TargetBuyGBX 4,490 ➝ GBX 4,760
6/30/2020Peel HuntReiterated RatingHold
6/18/2020Liberum CapitalBoost TargetBuyGBX 3,450 ➝ GBX 4,120
6/3/2020Peel HuntReiterated RatingHold
5/8/2020Peel HuntReiterated RatingHold
4/30/2020Peel HuntDowngradeHold
4/7/2020Peel HuntReiterated RatingBuy
4/1/2020HSBCBoost TargetBuyGBX 3,260 ➝ GBX 3,550
4/1/2020Peel HuntReiterated RatingBuy
3/23/2020Liberum CapitalReiterated RatingBuy
3/5/2020Peel HuntReiterated RatingBuy
2/27/2020Liberum CapitalReiterated RatingBuy
2/24/2020Peel HuntReiterated RatingBuy
2/13/2020Peel HuntReiterated RatingBuy
2/5/2020Peel HuntReiterated RatingBuy
1/6/2020Peel HuntReiterated RatingBuy
12/11/2019Peel HuntReiterated RatingBuy
12/5/2019Peel HuntReiterated RatingBuy
11/28/2019Liberum CapitalBoost TargetBuyGBX 2,800 ➝ GBX 3,450
11/20/2019Peel HuntReiterated RatingBuy
11/20/2019Liberum CapitalReiterated RatingBuy
11/15/2019Jefferies Financial GroupInitiated CoverageHoldGBX 3,272
11/14/2019Peel HuntReiterated RatingBuyGBX 3,200
11/14/2019Liberum CapitalReiterated RatingBuyGBX 2,800
11/13/2019HSBCBoost TargetBuyGBX 3,000 ➝ GBX 3,260
11/11/2019Peel HuntReiterated RatingBuyGBX 3,200
11/4/2019Peel HuntReiterated RatingBuy
10/21/2019Peel HuntReiterated RatingBuy
10/21/2019Liberum CapitalReiterated RatingBuy
10/7/2019Peel HuntReiterated RatingBuy
9/16/2019Peel HuntReiterated RatingBuy
9/11/2019Peel HuntReiterated RatingBuyGBX 3,200
9/10/2019Peel HuntReiterated RatingBuyGBX 3,200
9/6/2019Liberum CapitalReiterated RatingBuy
9/2/2019Peel HuntReiterated RatingBuy
8/22/2019Peel HuntReiterated RatingBuyGBX 3,200
8/22/2019Peel HuntReiterated RatingBuyGBX 3,200
8/1/2019Peel HuntReiterated RatingBuy
7/3/2019Peel HuntReiterated RatingBuy
6/4/2019Peel HuntReiterated RatingBuy
5/29/2019Stifel NicolausInitiated CoverageHoldGBX 2,685
5/28/2019Peel HuntReiterated RatingBuy
5/17/2019Liberum CapitalReiterated RatingBuy
5/16/2019Peel HuntBoost TargetBuyGBX 2,800 ➝ GBX 3,200
5/2/2019Peel HuntReiterated RatingBuy
4/12/2019Liberum CapitalReiterated RatingBuy
4/8/2019Peel HuntReiterated RatingBuy
4/2/2019Peel HuntReiterated RatingBuy
3/25/2019Liberum CapitalReiterated RatingBuy
3/25/2019Peel HuntReiterated RatingBuy
3/11/2019HSBCReiterated RatingBuyGBX 2,650 ➝ GBX 2,700
3/5/2019Liberum CapitalUpgradeBuyGBX 2,400 ➝ GBX 2,500
2/28/2019Liberum CapitalReiterated RatingHoldGBX 2,400
2/28/2019Peel HuntReiterated RatingBuy
2/12/2019HSBCInitiated CoverageBuyGBX 2,650
2/1/2019Peel HuntReiterated RatingBuy
1/3/2019Peel HuntReiterated RatingBuy
12/7/2018Liberum CapitalReiterated RatingHold
12/6/2018Kepler Capital MarketsUpgradeBuyGBX 2,475 ➝ GBX 2,630
12/6/2018Peel HuntReiterated RatingHold
11/15/2018Liberum CapitalReiterated RatingHold
11/15/2018Peel HuntReiterated RatingHold
11/1/2018Peel HuntReiterated RatingHold
10/12/2018Peel HuntDowngradeHold
10/2/2018Peel HuntReiterated RatingHold
9/13/2018Kepler Capital MarketsReiterated RatingHold
9/7/2018Kepler Capital MarketsBoost TargetHoldGBX 2,470 ➝ GBX 2,540
9/6/2018Liberum CapitalReiterated RatingHoldGBX 2,400
9/6/2018Peel HuntDowngradeHoldGBX 2,600
9/4/2018Peel HuntReiterated RatingBuy
8/1/2018Peel HuntReiterated RatingBuy
7/4/2018Kepler Capital MarketsBoost TargetHoldGBX 2,353 ➝ GBX 2,470
7/2/2018Peel HuntReiterated RatingBuy
6/27/2018Liberum CapitalReiterated RatingHold
6/21/2018Peel HuntReiterated RatingBuyGBX 2,600
6/5/2018Liberum CapitalReiterated RatingHold
5/30/2018Peel HuntReiterated RatingBuy
5/22/2018Liberum CapitalReiterated RatingHold
4/3/2018Peel HuntReiterated RatingBuyGBX 2,600
(Data available from 4/1/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Genus logo
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.
Read More

Today's Range

Now: GBX 2,874
Low: 2,874
High: 2,970

50 Day Range

MA: GBX 2,891.89
Low: 2,701.77
High: 3,168

52 Week Range

Now: GBX 2,874
Low: 2,186
High: 3,364

Volume

66,516 shs

Average Volume

91,205 shs

Market Capitalization

£1.89 billion

P/E Ratio

5,526.92

Dividend Yield

1.13%

Beta

0.43

Frequently Asked Questions

What sell-side analysts currently cover shares of Genus?

The following Wall Street sell-side analysts have issued reports on Genus in the last year: Peel Hunt.
View the latest analyst ratings for GNS.

What is the current price target for Genus?

1 Wall Street analysts have set twelve-month price targets for Genus in the last year. Their average twelve-month price target is GBX 4,500, suggesting a possible upside of 56.6%. Peel Hunt has the highest price target set, predicting GNS will reach GBX 4,500 in the next twelve months. Peel Hunt has the lowest price target set, forecasting a price of GBX 4,500 for Genus in the next year.
View the latest price targets for GNS.

What is the current consensus analyst rating for Genus?

Genus currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GNS, but not buy more shares or sell existing shares.
View the latest ratings for GNS.

What other companies compete with Genus?

Other companies that are similar to Genus include Oxford Nanopore Technologies, Abcam, PureTech Health, Ergomed and Silence Therapeutics. Learn More about companies similar to Genus.

How do I contact Genus' investor relations team?

Genus' physical mailing address is Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom. The company's listed phone number is +44-1256-347100. The official website for Genus is www.genusplc.com. Learn More about contacing Genus investor relations.